Nick Shah

Nick joined DiCE Molecules in 2018 and leads the In Vitro Pharmacology efforts as the team works to leverage chemical evolution in small molecule drug discovery. Prior to DiCE, Nick was a very early scientist at Flexus Biosciences / FLX Bio and helped discover two molecules that are currently in clinical testing for cancer immunotherapy: BMS-986205 in multiple Phase II trials & FLX475 in Phase I. Throughout his career, Nick has been deeply involved in assay development for drug discovery while leading project teams and managing multiple large-scale screening campaigns.

Nick completed a postdoctoral fellowship at Stanford University and his doctoral work at the University of Toronto.